DGAP-News: STRATEC Biomedical AG / Key word(s): AGM/EGM
STRATEC Annual General Meeting: Shareholders elect new Supervisory
Board and approve dividend increase
18.06.2014 / 18:00
---------------------------------------------------------------------
STRATEC Annual General Meeting: Shareholders elect new Supervisory Board
and approve dividend increase
Birkenfeld, June 18, 2014
At today's Annual General Meeting in Pforzheim, the shareholders of STRATEC
Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) approved all of the
agenda items put to the vote with large majorities in each case.
Prof. Dr. Stefanie Remmele, Landshut, Professor for medical engineering at
the Hochschule Landshut - University of Applied Sciences, was newly elected
to the three-member Supervisory Board and thus succeeds Prof. Dr. Hugo
Hämmerle. The previous Supervisory Board Chairman, Fred K. Brückner, and
the previous Deputy Supervisory Board Chairman, Wolfgang Wehmeyer, stood
for re-election and were once again elected to the supervisory body by the
Annual General Meeting.
At the subsequent constitutive meeting of the Supervisory Board, Fred K.
Brückner was once again elected as Chairman. Wolfgang Wehmeyer was
re-elected as Deputy Supervisory Board Chairman and as the independent
financial expert pursuant to § 100 (5) of the German Stock Corporation Act
(AktG).
STRATEC is distributing a dividend of EUR 0.60 per share to its
shareholders for the 2013 financial year (previous year: EUR 0.56). The
distribution total amounts to EUR 7.1 million and will be paid to
shareholders via their depository banks from June 20, 2014. The dividend
has thus been increased for the tenth year in succession since the
initiation of dividend payments in 2004.
Further information about the Annual General Meeting can be found on the
company's website at www.stratec.com/agm.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
18.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
273971 18.06.2014
DGAP-News: STRATEC Annual General Meeting: Shareholders elect new Supervisory Board and approve dividend increase
| Source: EQS Group AG